|

CLIC-1901 Clinical Trials

1 actively recruiting trial

Also known as: autologous anti-CD19 CAR-T cells

Pipeline

Phase 1/2: 1

Top Sponsors

  • Ottawa Hospital Research Institute1

Indications

  • Chronic Lymphocytic Leukemia1
  • Acute Lymphoblastic Leukemia1
  • Non-Hodgkin's Lymphoma1
  • Cancer1

Other1 trial

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.